--- title: "Scientific Industries, Inc. | 10-K: FY2025 Revenue: USD 5.054 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/281246185.md" datetime: "2026-03-31T21:06:05.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/281246185.md) - [en](https://longbridge.com/en/news/281246185.md) - [zh-HK](https://longbridge.com/zh-HK/news/281246185.md) --- # Scientific Industries, Inc. | 10-K: FY2025 Revenue: USD 5.054 M Revenue: As of FY2025, the actual value is USD 5.054 M. EPS: As of FY2025, the actual value is USD -0.11. EBIT: As of FY2025, the actual value is USD -8.03 M. #### Consolidated Net Revenue Scientific Industries, Inc. reported a consolidated net revenue of $5,053,800 for the year ended December 31, 2025, an increase of $256,700 (5.4%) from $4,797,100 in the prior year. This growth was primarily driven by a $645,100 rise in net revenues from the Benchtop Laboratory Equipment Operations, partially offset by a decrease in Bioprocessing Systems products sales. Foreign sales accounted for approximately 17% of net revenue in 2025, down from 23% in 2024. Sales to one major customer represented 31% of consolidated net revenues in 2025 (23% in 2024) and 42% of Benchtop Laboratory Equipment product sales (36% in 2024). Purchases from one vendor constituted 15.2% of consolidated net purchases in 2025 and 15.0% in 2024. #### Operational Metrics - **Gross Profit Percentage**: The gross profit percentage decreased to 25.8% in 2025 from 41.8% in 2024, mainly due to inventory write-offs in the Bioprocessing segment; without these write-offs, the gross profit percentage would have been 42.6%. - **General and Administrative Expenses**: These expenses decreased by $850,600 (-20.6%) to $3,268,800 in 2025 from $4,119,400 in 2024, attributed to cost savings initiatives in Bioprocessing Systems Operations and corporate expenses. - **Selling Expenses**: Selling expenses decreased by $60,800 (-1.9%) to $3,114,900 in 2025 from $3,205,700 in 2024, also due to cost savings in Bioprocessing Systems Operations. - **Research and Development Expenses**: A reduction of $410,200 (-14.2%) was observed, totaling $2,487,700 in 2025 compared to $2,897,900 in 2024, reflecting cost reductions by the Bioprocessing Systems Operations. - **Impairment of Intangible Assets**: An impairment of intangible assets amounting to $291,600 was recorded in 2025, with $0 in 2024, specifically against long-lived intangible assets in the Bioprocessing Systems Operations reporting unit. - **Loss from Continuing Operations**: The loss from continuing operations significantly improved to - $1,780,300 in 2025 from - $8,023,600 in 2024, primarily due to a $5,263,400 gain from the sale of the Genie® product line and reduced expenses. - **Total Other Income, Net**: Total other income, net, surged to $6,114,200 in 2025 from $192,800 in 2024, driven by the Genie product line sale gain and payroll tax reimbursements in the Bioprocessing Systems Operations segment. - **Income from Discontinued Operations**: Income from discontinued operations (Genie division) was $559,900 in 2025, a decrease from $1,578,200 in 2024. - **Consolidated Net Loss**: The consolidated net loss for Scientific Industries, Inc. was - $1,220,400 in 2025, a substantial improvement from - $6,445,400 in 2024. - **Accumulated Deficit**: The accumulated deficit stood at - $35,150,900 as of December 31, 2025. #### Cash Flow - **Cash and Cash Equivalents**: Cash and cash equivalents increased by $367,100, reaching $955,000 as of December 31, 2025, from $587,900 as of December 31, 2024. - **Net Cash Used in Operating Activities**: Net cash used in operating activities was - $8,149,600 in 2025, compared to - $3,046,100 in 2024, reflecting the sale of the Genie division. - **Net Cash Provided by Investing Activities**: Net cash provided by investing activities was $3,831,000 in 2025, up from $2,866,000 in 2024, primarily due to $7,614,200 in proceeds from the disposition of the discontinued Genie division. - **Net Cash Provided by Financing Activities**: Net cash provided by financing activities increased to $1,952,200 in 2025 from $645,700 in 2024, mainly due to the issuance of common stock and exercise of certain warrants. - **Net Cash Provided by Operating Activities of Discontinued Operations**: This was $2,694,800 in 2025, a reversal from - $637,400 used in 2024. #### Outlook / Guidance Scientific Industries, Inc. anticipates continued operating losses and negative cash flows from operations due to expenses for Bioprocessing Systems operations exceeding revenues. However, cash from the Genie division sale and other post-sale agreements is projected to fund operations for at least one year from the 2025 financial statements’ issuance date. To ensure continued operations, the company will need to reduce expenses, significantly increase revenues, or secure additional external capital. ### Related Stocks - [SCND.US](https://longbridge.com/en/quote/SCND.US.md) ## Related News & Research - [Can Bitcoin Hold the August 2024 Low?](https://longbridge.com/en/news/289503848.md) - [AFYREN’s Impact-Driven Bioeconomy Model Confirmed by B Corp™ Certification](https://longbridge.com/en/news/289278937.md) - [Beijing Biostar Pharmaceuticals Withdraws Three Resolutions From 2026 AGM Agenda](https://longbridge.com/en/news/289522789.md) - [Gamehaus Holdings Inc. Announces Unaudited Financial Results for the Third Quarter of Fiscal 2026 Ended March 31, 2026 | GMHS Stock News](https://longbridge.com/en/news/289035965.md) - [Shift in biosimilar commercial landscape essential for sector sustainability, expert says](https://longbridge.com/en/news/289174897.md)